Regen BioPharma (RGBP) Debt to Equity (2016 - 2024)
Historic Debt to Equity for Regen BioPharma (RGBP) over the last 9 years, with Q2 2024 value amounting to -$0.16.
- Regen BioPharma's Debt to Equity rose 247.79% to -$0.16 in Q2 2024 from the same period last year, while for Jun 2024 it was -$0.16, marking a year-over-year increase of 247.79%. This contributed to the annual value of -$0.19 for FY2023, which is 10246.57% down from last year.
- As of Q2 2024, Regen BioPharma's Debt to Equity stood at -$0.16, which was up 247.79% from -$0.18 recorded in Q1 2024.
- In the past 5 years, Regen BioPharma's Debt to Equity ranged from a high of -$0.04 in Q3 2020 and a low of -$0.87 during Q1 2022
- Over the past 5 years, Regen BioPharma's median Debt to Equity value was -$0.09 (recorded in 2022), while the average stood at -$0.15.
- As far as peak fluctuations go, Regen BioPharma's Debt to Equity plummeted by 116053.33% in 2022, and later soared by 8134.86% in 2023.
- Quarter analysis of 5 years shows Regen BioPharma's Debt to Equity stood at -$0.06 in 2020, then tumbled by 33.43% to -$0.08 in 2021, then tumbled by 100.74% to -$0.17 in 2022, then fell by 8.36% to -$0.18 in 2023, then rose by 14.76% to -$0.16 in 2024.
- Its Debt to Equity stands at -$0.16 for Q2 2024, versus -$0.18 for Q1 2024 and -$0.18 for Q4 2023.